HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Keros Therapeutics (NASDAQ:KROS) and maintained a $100 price target.
May 09, 2024 | 11:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating and a $100 price target on Keros Therapeutics.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100